COMPARISON OF ZIDOVUDINE COMBINATION AND TENOFOVIR COMBINATION ON THE EFFECTIVENESS OF THERAPY AND SIDE EFFECTS IN HIV/AIDS PATIENTS IN RSAL MINTOHARDJO
DOI:
https://doi.org/10.22159/ajpcr.2017.v10s5.23107Keywords:
HIVAIDS, Antiretroviral, Zidovudine, Tenofovir, CD4 , Side effectsAbstract
Objectives: Tenofovir-based therapy is a newly adopted first-line HIV/AIDS therapy regimen in Indonesia that is replacing the stavudine-based regimen. However, zidovudine-based regimens remain the first-line therapy for patients with HIV/AIDS. This study aimed to compare the effectiveness and incidence of adverse effects with hemoglobin (Hb) in both zidovudine- and tenofovir-based regimens in HIV/AIDS patients at Mintohardjo Hospital.
Methods: We used a cross-sectional comparative research design. The data analyzed were medical records of all HIV/AIDS patients treated through 2015.
Results: The sample included 75 patients in the zidovudine group and 53 patients in the tenofovir group. Wilcoxon signed-rank tests indicated that both combinations of therapy were effective in improving CD4+ cells. Initial CD4+ cell counts ≤ 200 cells/mm3 were 4.55 times better at increasing CD4+ cell counts when compared with an initial CD4+ > 200 cells/mm3. Chi-square results showed that both treatment combinations affected the decrease in Hb. Patients using the zidovudine combination had 4.59 times greater risk for a Hb decrease compared with the tenofovir combination.
Conclusions: Zidovudine- and tenofovir-based regimens had similar effectiveness in increasing CD4+ cell counts, but the tendency to cause anemia in tenofovir-based regimens was less than that of the zidovudine-based regimens.
Downloads
References
Ministry of Health Republic of Indonesia. Indonesia Health Profile 2014. Jakarta: Ministry of Health Republic of Indonesia; 2015.
Nelwan EJ. Adherence to highly active antiretroviral therapy (HAART) in HIV/AIDS patient. Acta Med Indones 2014;46(4):273-4.
World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents Recommendation for a Public Health Approach 2006 Revision. Geneva: WHO Press; 2006.
Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res 2010;132:386-9.
van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E, et al. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One 2012;7(7):e42029.
Dong BJ, Ward DJ, Chamberlain LA, Reddy YS, Ebrahimi R, Flaherty JF, et al. Safety and effectiveness of tenofovir/emtricitabine or lamivudine plus ritonavir boosted atazanavir in treatment experienced HIV infected adults at two urban private medical practices. J Antiviral Antiretrovir 2012;4(1):1-5.
Machado-Alba JE, González-Santos DM, Vidal-Guitart X. Effectiveness of antiretroviral treatment in patients from Pereira and Manizales. Rev Salud Publica (Bogota) 2011;13(3):492-503.
Indonesian Ministry of Health Regulation. Penanggulangan HIV dan AIDS. Jakarta: Indonesian Ministry of Health; 2013.
Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffman CJ. Comparison of tenofovir, zidovudine or stavudine as part of first line antiretroviral therapy in a resource limited setting: A cohort study. PLoS One 2013;8(5):e64459.
Medhanie EK, Muslimin L, Massi MN, Mangau M. Effectiveness of tenofovir/emtricitabine versus zidovudine/lamivudin in combination with efavirenz in antiretroviral-naïve HIV-infected patients in Eritrea. Int J Pharm Clin Res 2015;7(5):364-7.
Parkes-Ratanshi R, Katende D, Levin J, Wakeham K, Heiner G, Kamali A, et al. Development of severe anemia and changes in hemoglobin in a cohort of HIV-infected Ugandan adults receiving zidovudine-, stavudine-, and tenofovir-containing antiretroviral regimens. J Int Assoc Provid AIDS Care 2015;14(5):455-62.
Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, Maxwell N, et al. Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. J Int AIDS Soc 2012;15(1):5.
James A, Sudhakar R, Yasaswini B, Manimalika K, Kumar TR, Sivaskumar T. A case report on zidovudine induced anemia and its management in HIV-1 infected patient. Int J Pharm Sci Rev Res 2014;27(2):67-8.
Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: A double-edged sword? J Am Soc Nephrol 2013;24(10):1519-27.
Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect 2012;18(5):449-58.
Meidani M, Rezaei F, Maracy MR, Avijgan M, Tayeri K. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. J Res Med Sci 2012;17(2):138-42.
Lubyayi L, Shkedy Z, Kajungu D, Mwehire D, Kirungi C, Kawuma E, et al. Evolution of CD4 cell counts over time for HIV/AIDS patients on antiretroviral therapy (ART) in Mildmay Uganda. Biomet Biostat Int J 2015;2(2):2-10.
Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayuehu M, Kindeya F. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: A retrospective cross-sectional study. PLoS One 2015;10(3):e0122583.
Bishop JD, DeShields S, Cunningham T, Troy SB. CD4 count recovery after initiation of antiretroviral therapy in patients infected with human immunodeficiency virus. Am J Med Sci 2016;352(3):239-44.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
